Dicerna Pharmaceuticals Inc to Post Q3 2018 Earnings of ($0.27) Per Share, SunTrust Banks Forecasts (DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Investment analysts at SunTrust Banks lifted their Q3 2018 earnings per share estimates for shares of Dicerna Pharmaceuticals in a research note issued to investors on Monday, August 13th. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will earn ($0.27) per share for the quarter, up from their prior estimate of ($0.28). SunTrust Banks also issued estimates for Dicerna Pharmaceuticals’ Q4 2018 earnings at ($0.26) EPS, FY2018 earnings at ($1.09) EPS, Q1 2019 earnings at ($0.30) EPS, Q2 2019 earnings at ($0.27) EPS, Q3 2019 earnings at ($0.31) EPS, Q4 2019 earnings at ($0.31) EPS, FY2019 earnings at ($1.15) EPS, FY2020 earnings at ($0.93) EPS, FY2021 earnings at ($0.91) EPS and FY2022 earnings at ($0.63) EPS.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.26). The firm had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.79 million. Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%.

A number of other analysts also recently issued reports on DRNA. Evercore ISI reiterated an “outperform” rating and issued a $17.00 price target (up from $14.00) on shares of Dicerna Pharmaceuticals in a report on Friday, April 20th. Cowen reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, April 24th. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 4th. Finally, HC Wainwright reiterated a “hold” rating and issued a $14.00 price target on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $14.54.

Shares of NASDAQ DRNA opened at $15.07 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.40 and a current ratio of 5.40. The firm has a market capitalization of $773.07 million, a price-to-earnings ratio of -3.99 and a beta of 2.33. Dicerna Pharmaceuticals has a 52-week low of $2.69 and a 52-week high of $16.32.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. California Public Employees Retirement System increased its holdings in Dicerna Pharmaceuticals by 39.0% in the 2nd quarter. California Public Employees Retirement System now owns 57,000 shares of the biopharmaceutical company’s stock valued at $698,000 after acquiring an additional 16,000 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Dicerna Pharmaceuticals in the 2nd quarter worth $266,000. Metropolitan Life Insurance Co. NY purchased a new position in shares of Dicerna Pharmaceuticals in the 2nd quarter worth $188,000. Voya Investment Management LLC purchased a new position in shares of Dicerna Pharmaceuticals in the 2nd quarter worth $208,000. Finally, RTW Investments LP grew its stake in shares of Dicerna Pharmaceuticals by 0.3% in the 2nd quarter. RTW Investments LP now owns 5,044,813 shares of the biopharmaceutical company’s stock worth $61,799,000 after buying an additional 15,351 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Featured Article: Fundamental Analysis and Individual Investors

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply